Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

VNUS Medical Technologies: Firm grosses $60 mil. via Oct. 20 initial public offering of 4 mil. shares at $15 each. An additional 1.4 mil. shares were sold by prior shareholders. One-third of the proceeds will go toward expansion of sales and marketing activities for the VNUS Closure minimally invasive venous reflux disease treatment. Cleared via 510(k) in March 1999, the device uses radiofrequency heat to close diseased saphenous veins. The next-generation RFG2 RF generator, which debuted Oct. 26, features continuous monitoring of vein wall temperature and impedance. The 154-employee firm generated revenue of $16.9 mil. for the first half of 2004, up 101% from a year ago. About 75% of revenue is derived from disposable catheters used with the RF generators. VNUS, which estimates the applicable U.S. market at 800,000 patients annually, has been profitable since Q4 2003 but has accrued losses of $43.2 mil. since its inception in 1995. VNUS planned to go public in August 2000 but withdrew its prospectus in April 2001 amidst broader market weakness (1"The Gray Sheet" Aug. 28, 2000, p. 13). The firm re-filed with SEC in July and now trades on Nasdaq as "VNUS." IPO underwriters include Banc of America, Piper Jaffray and William Blair & Company...

You may also be interested in...



Vnus To Double Closure Sales Force Following $57.5 Mil. IPO

Vnus Medical Technologies intends to spend at least $8 mil. of the proceeds from a proposed $57.5 mil. initial public offering on sales, marketing and reimbursement activities, the company disclosed in an Aug. 18 prospectus outlining the deal.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

UsernamePublicRestriction

Register

MT021100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel